These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
131 related items for PubMed ID: 38470990
1. Pretreatment ocular blood flow and retinal oxygen metabolism in the acute uveitic phase is associated with final outcome in Vogt-Koyanagi-Harada disease. Abu El-Asrar AM, AlBloushi AF, Alzubaidi A, Gikandi PW, Stefánsson E. Acta Ophthalmol; 2024 Sep; 102(6):720-727. PubMed ID: 38470990 [Abstract] [Full Text] [Related]
2. Acute uveitic phase of Vogt-Koyanagi-Harada disease: optic nerve head swelling, ocular blood flow and retinal oxygen metabolism. Abu El-Asrar AM, AlBloushi AF, Gikandi PW, Alzubaidi A, Stefánsson E. Eye (Lond); 2023 May; 37(7):1432-1438. PubMed ID: 35768722 [Abstract] [Full Text] [Related]
3. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM, AlBloushi AF, Gikandi PW, Hardarson SH, Stefánsson E. Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260 [Abstract] [Full Text] [Related]
4. Effect of immunosuppressive therapy on ocular blood flow in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM, Alsarhani W, Alzubaidi A, Gikandi PW. Acta Ophthalmol; 2021 Dec; 99(8):e1405-e1414. PubMed ID: 33719161 [Abstract] [Full Text] [Related]
5. Prognostic value of pretreatment indocyanine green angiography in the acute uveitic phase of Vogt-Koyanagi-Harada disease. Tobaigy MF, Abouammoh MA, AlBloushi AF, Saifaldein AA, Gikandi P, Almousa AN, Herbort CP, El-Asrar AA. Acta Ophthalmol; 2024 Aug; 102(5):e679-e686. PubMed ID: 38131519 [Abstract] [Full Text] [Related]
14. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease. Feng H, Chen W, Yang J, Kong H, Li H, He Y, Wang H. BMC Ophthalmol; 2024 Jun 07; 24(1):238. PubMed ID: 38849758 [Abstract] [Full Text] [Related]